JAC Advance Access originally published online on November 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2002) 50, 1017-1026
© 2002 The British Society for Antimicrobial Chemotherapy
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin
1 CPL Associates, LLC, 3980 Sheridan Drive, Suite 501, Amherst, NY 14226; 2 School of Pharmacy, University at Buffalo, Buffalo, NY, USA
Received 6 March 2002; returned 4 July 2002; revised 25 July 2002; accepted 21 August 2002
Objective: The incidence of infections caused by methicillin-resistant Staphylococcus aureus continues to increase annually. Unfortunately, only a few therapeutic agents are available for the treatment of patients with such infections and all of the existing drugs have limitations. A pressing need exists, therefore, to identify new antibiotics for use in this clinical setting. The efficacy and safety of linezolid were studied in a compassionate use treatment programme and the results of treating a subset of patients with S. aureus infections are presented here.
Methods: Patients received linezolid in a dosage of 600 mg intravenously (iv) and/or orally twice daily. Clinical and bacteriological responses were assessed after a minimum of 7 days and following completion of therapy.
Results: Seven hundred and ninety-six patients who suffered 828 episodes of infection were enrolled in the linezolid compassionate use protocol. Of these, 183 patients received linezolid for 191 infections caused by S. aureus; in 151 cases, patients were intolerant of vancomycin, had a mixed S. aureus/vancomycin-resistant enterococcal infection or had no iv access, and, in 40 cases, patients had failed to respond to treatment with vancomycin. The median age of the patients was 57 years (range 14–93 years) and 53.9% were female. The predominant sites of infection were as follows: bone or joint (27.2%); skin and skin structure (25.1%); bloodstream (20.9%); and lower respiratory tract (12.6%). The clinical success rates in the clinically evaluable and all-treated populations were 83.9% and 62.3%, respectively, whereas the bacteriological eradication rates were 76.9% and 70.2% in the bacteriologically evaluable and all-treated populations, respectively. Linezolid was well tolerated. In 76 (39.8%) of the 191 episodes of infection, patients experienced one or more adverse events or exhibited one or more abnormal laboratory results; in 35 (18.3%) of the 191 cases it was necessary to discontinue treatment. Gastrointestinal tract-related symptoms (nausea, vomiting and diarrhoea) were the most common possibly or probably related adverse events and the most common reasons for drug discontinuation.
Conclusions: Linezolid was effective and well tolerated in patients with S. aureus infections who were enrolled in this compassionate use protocol.
* Corresponding author. Tel: +1-716-839-4931; Fax: +1-716-839-5138; E-mail: schentag{at}buffalo.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A. Moise, D. S. Smyth, D. A. Robinson, N. El-Fawal, C. McCalla, and G. Sakoulas Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies J. Antimicrob. Chemother., May 1, 2009; 63(5): 873 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A Moise, R. S Castro, C. Sul, A. Forrest, and G. Sakoulas Relationship of Linezolid Minimum Inhibitory Concentration and Time to Bacterial Eradication in Treatment for Methicillin-Resistant Staphylococcus aureus Infection Ann. Pharmacother., April 1, 2008; 42(4): 592 - 593. [Full Text] [PDF]
|
|
|
|
|
|
G. N Forrest, B. J Donovan, K. C Lamp, and L. V Friedrich Clinical Experience with Daptomycin for the Treatment of Patients with Documented Gram-Positive Septic Arthritis Ann. Pharmacother., February 1, 2008; 42(2): 213 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Moise, D. S. Smyth, N. El-Fawal, D. A. Robinson, P. N. Holden, A. Forrest, and G. Sakoulas Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia J. Antimicrob. Chemother., January 1, 2008; 61(1): 85 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Moise, G. Sakoulas, A. Forrest, and J. J. Schentag Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2582 - 2586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Gemmell, D. I. Edwards, A. P. Fraise, F. K. Gould, G. L. Ridgway, R. E. Warren, and on behalf of the Joint Working Party of the Britis Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK J. Antimicrob. Chemother., April 1, 2006; 57(4): 589 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Giannoudis, J. Parker, and M. H. Wilcox Methicillin-resistant Staphylococcus aureus in trauma and orthopaedic practice J Bone Joint Surg Br, June 1, 2005; 87-B(6): 749 - 754. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sakoulas, P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering Jr., and G. M. Eliopoulos Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia J. Clin. Microbiol., June 1, 2004; 42(6): 2398 - 2402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mogenet, S. Raetz-Dillon, J.-M. Canonge, M. Archambaud, and E. Bonnet Successful Treatment of Staphylococcus epidermidis Hip Prosthesis Infection with Oral Linezolid Ann. Pharmacother., June 1, 2004; 38(6): 986 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Parra-Ruiz, M. Martinez, R. Antelo-Lorenzo, and J. Hernandez-Quero Antimicrobials in the treatment of orthopaedic prosthetic infections J. Antimicrob. Chemother., May 1, 2004; 53(5): 886 - 887. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Filipek, M. Rzychon, A. Oleksy, M. Gruca, A. Dubin, J. Potempa, and M. Bochtler The Staphostatin-Staphopain Complex: A FORWARD BINDING INHIBITOR IN COMPLEX WITH ITS TARGET CYSTEINE PROTEASE J. Biol. Chem., October 17, 2003; 278(42): 40959 - 40966. [Abstract] [Full Text] [PDF]
|
|